Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GIB-7 (GI Biome Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- GI Biome
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
GIB-7 is an investigational synbiotic therapeutic developed by GI Biome (an affiliate of GI Innovation) using its proprietary 'Microbiome+ Herbal Therapy' platform. The formulation consists of three patented probiotic strains combined with specific herbal ingredients. GIB-7 is designed to address aging-related physiological decline by modulating gut microbiome diversity, regulating circadian rhythms, and enhancing muscle strength. It is currently in Phase 2a clinical development in Australia and South Korea, where it is being evaluated both as a monotherapy and in combination with GI-102 (an intravenous IL-2-based immunotherapy) for healthy adults, elderly individuals, and cancer survivors. The program is recognized as a semi-finalist in the XPRIZE Healthspan competition.
Beyond the preview
Go deeper on GIB-7 (GI Biome Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GIB-7 (GI Biome Co., Ltd.).